MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit.
NPJ Breast Cancer. 2021 Jan 4;7(1):2. doi: 10.1038/s41523-020-00210-8.
NPJ Breast Cancer. 2021.
PMID: 33398005
Free PMC article.